we can reliably supply
doses

We are committed to ensuring availability nationwide

PYLARIFY TruVu includes a radiolytic stabilizer to increase batch production¹*

With PYLARIFY TruVu you can expect:

POTENTIAL FOR
Increased availability and manufacturing reliability with additional doses per batch¹

*PYLARIFY TruVu injection is supplied as 37 MBq/mL to 4,440 MBq/mL (2 mCi/mL to 120 mCi/mL) of piflufolastat F 18 in up to 55 mL at end of synthesis. The original piflufolastat F 18 is supplied at a strength of 37 MBq/mL to 2,960 MBq/mL (1 mCi/mL to 80 mCi/mL).

Consistent supply and distribution

PYLARIFY TruVu is built on an extensive, multi-partner F 18 distributor supply network. We are committed to ensuring convenient and reliable supply when you and your patients need it.

For information about ordering PYLARIFY TruVu for your imaging site, and how to get started, contact PYLARIFY TruVu Customer Support at 1‑800‑362‑2668 M‑F 8:30 am‑8:00 pm ET, or email cspyl@lantheus.com.

PYLARIFY TruVu manufacturing site

Available now

Alabama, Birmingham

Alabama, Mobile

Arizona, Phoenix

Arkansas, Little Rock

California, Culver City

California, Gilroy

California, Loma Linda

California, Los Angeles

California, Sacramento

Colorado, Denver

Florida, Fort Lauderdale

Florida, Jacksonville

Florida, Sanford

Florida, Tampa

Georgia, Atlanta

Georgia, Norcross

Illinois, Chicago

Illinois, Romeoville

Iowa, Davenport

Kansas, Kansas City

Kentucky, Louisville

Louisiana, Covington

Massachusetts, Boston

Massachusetts, Haverhill

Michigan, Detroit

Michigan, Grand Rapids

Minnesota, Minneapolis

Missouri, Columbia

Missouri, Kansas City

Nevada, Las Vegas

New Jersey, Hackensack

New Jersey, Somerset

New Jersey, Totowa

New Mexico, Albuquerque

New York, Albany*

New York, Bronx

North Carolina, Raleigh

North Carolina, Winston-Salem

Ohio, Cincinnati

Ohio, Cleveland*

Oklahoma, Tulsa

Oregon, Portland

Pennsylvania, Philadelphia

Puerto Rico, San Juan

South Carolina, Columbia

South Carolina, Duncan

Tennessee, Gray

Tennessee, Knoxville

Tennessee, Nashville

Texas, Austin

Texas, Dallas*

Texas, Houston*

Utah, Salt Lake City

Virginia, Salem

Virginia, Sterling

Washington, Seattle

Washington, Spokane

West Virginia, Morgantown

Wisconsin, Milwaukee

*2 manufacturing sites.

Partners included but not limited to

If a manufacturing site has issues and cannot deliver, our dedicated Lantheus Customer Experience team can help

This team can:

Explore all options to meet demand
Monitor and address customer escalations
Identify manufacturing site redundancy
Communicate manufacturing site calibration times

Availability you can count on

Built on a network of²:

1540+ imaging centers

in 48 states and Puerto Rico

We are expanding toward the future with PYLARIFY TruVu

PYLARIFY TruVu imaging center

Release times and a half-life of 109.8 minutes to meet the high patient volume and enable more flexible patient scheduling

To report suspected adverse reactions for PYLARIFY TRUVU, call 1-800-362-2668 or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see the full Prescribing Information for PYLARIFY TRUVU.

INDICATION

PYLARIFY TRUVU (piflufolastat F 18) Injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

with suspected metastasis who are candidates for initial definitive therapy.
with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Risk of Image Misinterpretation

Imaging interpretation errors can occur with PYLARIFY TRUVU imaging. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer. The performance of PYLARIFY TRUVU for imaging biochemical evidence of recurrence of prostate cancer seems to be affected by serum PSA levels. The performance of PYLARIFY TRUVU for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by risk factors such as Gleason score and tumor stage. PYLARIFY TRUVU uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes and in normal tissues. Clinical correlation, which may include histopathological evaluation, is recommended.

Hypersensitivity Reactions

Monitor patients for hypersensitivity reactions, particularly those with a history of allergy to other drugs and foods. Reactions may be delayed. Always have trained staff and resuscitation equipment available.

Radiation Risks

PYLARIFY TRUVU exposes patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration.

Adverse Reactions

The most frequently reported adverse reactions were headaches, dysgeusia and fatigue, occurring at rate of ≤2% during clinical studies. In addition, a delayed hypersensitivity reaction was reported in one patient (0.2%) with a history of allergic reactions.

Drug Interactions

Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, may result in changes in uptake of PYLARIFY TRUVU in prostate cancer. The effect of these therapies on performance of PYLARIFY TRUVU PET has not been established.